AlphAIAlphAI — Financial news for AI agents
scanx.tradeSEP 183 min read

Trex Bio files for Nasdaq IPO; Eli Lilly eyes 19.9% stake

Trex Bio filed for a Nasdaq IPO under the ticker TRXB, with Eli Lilly planning to acquire up to 19.9% stake. The company's pipeline includes TRB-071 and TRB-051, with Eli Lilly partnering on the latter. Underwriters include J.P. Morgan, Evercore ISI, and others. The IPO aims to raise capital and establish a strategic partnership with Eli Lilly.

Original reporting
scanx.trade
Published Sep 18, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Trex Bio files for Nasdaq IPO; Eli Lilly eyes 19.9% stake — source image
Source · scanx.trade
Decision brief

The 30-second read

Med
01

Why it matters

The strategic investment by Eli Lilly signals confidence in the pipeline, likely attracting institutional demand for the IPO.

02

Market read

First disclosure of a biotech IPO with a major pharma partner, creating a new tradable asset and sector interest.

03

What to watch

Potential regulatory hurdles for the CD30 programs and the timing of Phase 2a trials could affect valuation.

Relevance 8/10Novelty 8/10Timing: upon filing

Background

Trex Bio is a biotech developing CD30 agonist antibodies; the IPO aims to fund its pipeline.

Market effects

Sector

Adds credibility to the biotech sector and may spur interest in similar early‑stage therapeutic companies.

Regional

Boosts US biotech IPO pipeline perception, especially for companies seeking strategic pharma partners.

Global

Highlights cross‑border collaboration between US biotech and large pharma, relevant to global healthcare investors.

Counterpoint

What could challenge this read

The large stake by Eli Lilly could dilute existing shareholders and give the pharma giant outsized control.

Key entities

  • company
    Trex Bio

    Biotech filing for Nasdaq IPO under ticker TRXB.

  • company
    Eli Lilly

    Potential strategic investor planning to acquire up to 19.9% of Trex Bio.

Read at source← All news

Related articles

OCT 9
HighAI 8/10

TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO

TRex Bio filed for a Nasdaq IPO, offering 8,333,334 shares at $14.00 each, aiming to raise $116.7 million. The company, focused on immunoregulatory medicines, plans to use proceeds for clinical trials and general corporate purposes. Eli Lilly has shown interest in purchasing shares. TRex Bio's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027.

tradingview.com2 min
OCT 9
HighAI 8/10

TRex Bio raises $116.7 million in IPO priced at $14 a share

TRex Bio Inc. raised $116.7 million in its IPO, priced at $14 per share. J.P. Morgan and Evercore led the offering, indicating institutional confidence. The company focuses on immunology, an area of sustained investor interest. All shares were pre-allocated to institutional buyers, with the first public trading opportunity upcoming.

247wallst.com2 min
OCT 9
HighAI 8/10

TRex Bio IPO raises $116.7 million, prices at bottom of range

TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.

finance.yahoo.com2 min
OCT 9
HighAI 8/10

TRex Bio prices $117M IPO to support immune drug work

TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.

finance.yahoo.com2 min
OCT 9
HighAI 9/10

TRex Bio, Inc. Prices $116.7M IPO at $14

TRex Bio priced 8.3M shares at $14 each, raising $116.7M in its IPO. Trading begins Oct. 9 on Nasdaq under ticker TRXB. Underwriters have a 30-day option for 1.25M more shares. The company plans to use proceeds for its clinical-stage immunology pipeline.

tradingview.com1 min